Back to Search
DANA GUYER, M.D.
M.D.
Internal Medicine Physician
NPI: 1215101605IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
255986(MA)
Pediatrics Physician
Pediatrics
Code: 208000000X
255986(MA)
CMS Specialties
PrimaryINTERNAL MEDICINE
Education
VANDERBILT UNIVERSITY SCHOOL OF MEDICINE
Class of 2008
Research & Publications (20)
Sat, the secreted autotransporter toxin of uropathogenic Escherichia coli, is a vacuolating cytotoxin for bladder and kidney epithelial cells.
PMID 12117966·Infect Immun·2002
7-preclinical
Secreted proteins and other features specific to uropathogenic Escherichia coli.
PMID 11171010·J Infect Dis·2001
6-review
The utility of ranking ophthalmology centers. The ranking of ophthalmology centers in ophthalmology and lay publications is appropriate for medicine in today's business world.
PMID 11074818·Arch Ophthalmol·2000
8-other
Identification of sat, an autotransporter toxin produced by uropathogenic Escherichia coli.
PMID 11029690·Mol Microbiol·2000
7-preclinical
Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.
PMID 19365011·Arch Ophthalmol·2009
3-trial
The pharmaceutical management system at Shade Tree Family Clinic: a medical student-run free clinic's experience.
PMID 18850398·Inform Health Soc Care·2008
8-other
A new optical parametric amplifier based on lithium thioindate used for sum frequency generation vibrational spectroscopic studies of the amide I mode of an interfacial model peptide.
PMID 18801230·Appl Spectrosc·2008
8-other
Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.
PMID 18614570·Br J Ophthalmol·2008
4-observational
Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
PMID 16828500·Ophthalmology·2006
4-observational
Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
PMID 16647134·Ophthalmology·2006
4-observational
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
PMID 16518379·Nat Rev Drug Discov·2006
6-review
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.
PMID 16343627·Ophthalmology·2006
8-other
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.
PMID 16154196·Ophthalmology·2005
3-trial
WGA-coated yttrium oxide beads enable an imaging-based adenosine 2a receptor binding scintillation proximity assay suitable for high throughput screening.
PMID 15285910·Assay Drug Dev Technol·2004
8-other
Accelerated drug development through combined phase 2/3 clinical trial design.
PMID 15249371·Arch Ophthalmol·2004
8-other
Age-dependent variations in the drusen fluorescence on indocyanine green angiography.
PMID 12880453·Clin Exp Ophthalmol·2003
4-observational
Optical coherence tomography findings in nicotinic acid maculopathy.
PMID 12788145·Am J Ophthalmol·2003
5-case
Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin.
PMID 12095809·Am J Ophthalmol·2002
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- ONE HOSPITAL ROAD
OAK BLUFFS, MA 02557 - Phone
- (508) 693-0410
Quick Facts
- NPI
- 1215101605
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 18
- Publications
- 20
Are you this provider?
Claim Your Profile